Clinical Relevance of [18F]Florbetaben and [18F]FDG PET/CT Imaging on the Management of Patients with Dementia.

摘要: PET of β-Amyloid plaques (Aβ) using [18F]florbetaben ([18F]FBB) and [18F]fluorodeoxyglucose ([18F]FDG) increasingly aid clinicians in early diagnosis dementia, including Alzheimer’s disease (AD), frontotemporal disease, dementia with Lewy bodies, vascular dementia. The aim this retrospective analysis was to evaluate clinical relevance [18F]FBB, [18F]FDG complimentary CSF measurements patients suspected In study, 40 clinically or history underwent (1) measurement Aβ peptides, total tau, p-tau protein levels the cerebrospinal fluid (CSF) compared healthy controls (HC); (2) neuropsychological assessment, which included Consortium Establish a Registry for Disease assessment battery (CERAD-NAB); (3) [18F]FBB imaging within an average 3 weeks. subjects were 15 days stratified PET, as HC, mild cognitive impaired (MCI) Alzheimer´s disease. predictive dementia-related decline values supporting measurements. images evaluated visually quantitatively standard uptake value ratios (SUVR). Twenty-one (52.5%) amyloid-positive (Aβ+), median neocortical SUVR 1.80 AD versus 1.20 relative respective 19 (47.5 %) amyloid-negative (Aβ-) subjects. Moreover, confirmed sub-group 10 good role by correlation between amyloid pathology brain glucose metabolism 8 out results suggest combined retention CFS serving management our Therefore, is helpful tool differential diagnosis, supports patients’ well treatment.